CLINICAL_TRIALS
trial_result
· 2022-03-15
Clinical Trial Update: A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis [Phase 2]
Summary
Phase 2 long-term safety study for GLPG1690 in systemic sclerosis has been terminated with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Galapagos NV | Conditions: Systemic Sclerosis | Phase 2 | Status: TERMINATED | Results posted: 2022-03-15